CA2446355A1 - Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable - Google Patents

Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable Download PDF

Info

Publication number
CA2446355A1
CA2446355A1 CA002446355A CA2446355A CA2446355A1 CA 2446355 A1 CA2446355 A1 CA 2446355A1 CA 002446355 A CA002446355 A CA 002446355A CA 2446355 A CA2446355 A CA 2446355A CA 2446355 A1 CA2446355 A1 CA 2446355A1
Authority
CA
Canada
Prior art keywords
delivery system
dlos
system comprises
mucosal adjuvant
los
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446355A
Other languages
English (en)
Inventor
Xin-Xing Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446355A1 publication Critical patent/CA2446355A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une immunisation intranasale qui fait appel à un lipooligosaccharide détoxifié provenant d'un Haemophilus influenzae ou d'un Moraxella catarrhalis non typable.
CA002446355A 2001-05-03 2001-10-16 Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable Abandoned CA2446355A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28869501P 2001-05-03 2001-05-03
US60/288,695 2001-05-03
PCT/US2001/032331 WO2002089839A1 (fr) 2001-05-03 2001-10-16 Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable

Publications (1)

Publication Number Publication Date
CA2446355A1 true CA2446355A1 (fr) 2002-11-14

Family

ID=23108227

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446355A Abandoned CA2446355A1 (fr) 2001-05-03 2001-10-16 Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable

Country Status (2)

Country Link
CA (1) CA2446355A1 (fr)
WO (1) WO2002089839A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457027C (fr) 2001-08-16 2011-10-11 Medical Research Council Microparticules de chitine et applications medicales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462210B1 (fr) * 1989-03-09 1994-09-07 Praxis Biologics, Inc. Vaccins contre les haemophilus influenzae inclassifiables
US5770213A (en) * 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
CA2315746A1 (fr) * 1998-01-13 1999-07-22 The Government Of The United States Of America Vaccin a base de lipooligosaccharide destine a la prevention d'infections dues a moraxella (branhamella) catarrhalis chez les mammaliens

Also Published As

Publication number Publication date
WO2002089839A1 (fr) 2002-11-14

Similar Documents

Publication Publication Date Title
JP4091026B2 (ja) 複数種オリゴ糖の糖接合体型の細菌性髄膜炎ワクチン
US6607725B2 (en) Conjugate vaccine for nontypeable Haemophilus influenzae
US6531131B1 (en) Conjugate vaccine for Neisseria meningitidis
EP2170391B1 (fr) Polysaccharides modifiés pour vaccins conjugués
JP4662537B2 (ja) 細菌性髄膜炎に関する粘膜組合せワクチン
CA2090673A1 (fr) Compositons de vaccin ameliorees
EP0639081A1 (fr) Compositions de vaccin a administration par la muqueuse
US6685949B1 (en) Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
US7641906B2 (en) Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis
Bergquist et al. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate
US9310381B2 (en) Engineered type IV pilin of Clostridium difficile
Coughlin et al. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines
EP0623026A1 (fr) Vaccin conjugue a base de toxine du cholera et de lypopolysaccharide (lps) detoxique, utilise pour la prevention du cholera
EP0471954A2 (fr) Conjugué immunogénique d'oligosaccharides non toxiques dérivés du lipooligosaccharide de Bordetella pertussis
CA2446355A1 (fr) Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable
AU2003200964B2 (en) Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) Catarrhalis Infections in Mammals
AU2002211782A1 (en) Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis
JP5967585B2 (ja) ワクチンとして使用される無毒化大腸菌易熱性エンテロトキシン（ｌｔ）との多糖結合
Fattom Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man
MXPA00006678A (en) Lipooligosaccharide-based vaccine for prevention of moraxella
CN116898960A (zh) 细菌多糖蛋白缀合物及其应用
CN110652585A (zh) 多糖-蛋白缀合物免疫制剂及其制备与应用
Franěk et al. Antibacterial immunity of lower airways: local or localized?

Legal Events

Date Code Title Description
FZDE Discontinued